$44.93
1.81%
Nasdaq, Oct 10, 10:01 pm CET
ISIN
US22663K1079
Symbol
CRNX

Crinetics Pharmaceuticals Inc Stock price

$44.93
+9.93 28.37% 1M
+18.08 67.34% 6M
-6.20 12.13% YTD
-6.85 13.23% 1Y
+28.04 166.02% 3Y
+28.76 177.86% 5Y
+20.42 83.31% 10Y
+20.42 83.31% 20Y
Nasdaq, Closing price Fri, Oct 10 2025
-0.83 1.81%
ISIN
US22663K1079
Symbol
CRNX
Industry

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$3.0b
Net debt
positive
Cash
$1.2b
Shares outstanding
94.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3,044.1 | 715.0
EV/Sales
2,183.4 | 512.8
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
92.4%
Return on Equity
-22.5%
ROCE
-34.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.4m | $5.9m
EBITDA
$-419.6m | $-476.0m
EBIT
$-423.1m | $-510.2m
Net Income
$-369.8m | $-456.3m
Free Cash Flow
$-307.8m
Growth (TTM | estimate)
Revenue
0.0% | 469.0%
EBITDA
-51.9% | -41.6%
EBIT
-52.2% | -50.6%
Net Income
-43.0% | -52.9%
Free Cash Flow
-66.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-30,144.9% | -8,043.4%
EBIT
-30,392.2%
Net
-26,568.5% | -7,710.8%
Free Cash Flow
-22,111.9%
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
15.0%
Employees
437
Rev per Employee
$0.0
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

20x Buy
87%
3x Hold
13%

Analyst Opinions

23 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.39 1.39
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 139 139
78% 78%
10,032%
- Research and Development Expense 285 285
42% 42%
20,504%
-420 -420
52% 52%
-30,188%
- Depreciation and Amortization 3.44 3.44
94% 94%
247%
EBIT (Operating Income) EBIT -423 -423
52% 52%
-30,436%
Net Profit -370 -370
43% 43%
-26,606%

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees,...
Neutral
GlobeNewsWire
6 days ago
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Positive
The Motley Fool
15 days ago
Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept.
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 437
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today